Work

Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine as second-line treatment for HER2-positive metastatic breast cancer

Year: 2026

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2026.2718415

Authors: Gu Shilong, Guo Hao

Institutions: Inner Mongolia People's Hospital, Inner Mongolia Medical University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7203626303

FWCI:

Cites: 27

Cited by:

Related to: